WuXi STA closes acquisition of a manufacturing facility in Couvet from Bristol Myers Squibb

On July 30, 2021, WuXi STA, a subsidiary of WuXi AppTec, a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry with global operations, whose shares are listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, successfully completed the acquisition of a state-of-the-art tablet & capsule manufacturing and packaging facility in Couvet, Switzerland, from Bristol Myers Squibb. 

The acquisition included the site’s operations and assets, among which the plant and equipment, as well as the workforce with technical capabilities and expertise.

Lenz & Staehelin acted as Swiss legal advisor to WuXi STA in this transaction. The team was led by partner Andreas Rötheli (co-head Corporate and M&A) and included associates Ralph Kaufmann and Roman Graf (Corporate and M&A), Giulia Neri-Castracane and Cécile Vulliemin (Real Estate), Sevan Antreasyan (IP, Regulatory & Life Sciences), Sandrine Kreiner, Prisca Cattaneo and Bertrand Donzé (Employment), and Benoît Biedermann (Tax). DLA Piper Hong Kong and New York acted as lead counsel to WuXi STA in this transaction.